Strategic Market Development Director – Rare Diseases Launch

REGENXBIO Inc.; United States; Hybrid; USD 187,000 - 265,000; Full time

Benefits offered by this job

Annual bonus

Education assistance

Retirement plan with employer match

Stock options

Summer hours

Job summary

REGENXBIO Inc. is seeking a Market Development Director to guide regional strategy and launch readiness for rare and neuromuscular therapies. You will lead engagement with treatment centers, align with Sales, Medical Affairs, and Market Access, and shape regional strategies to drive access and adoption.

The role requires 5+ years in biotech/pharma commercial roles, a BA/BS, and a strong track record in rare diseases with international collaboration. Travel up to 60% is expected.

Qualifications

• Minimum of 5+ years in a commercial, market development, or strategic customer engagement role within biotech/pharma.
• Bachelor’s degree required; advanced degree preferred (MBA, PhD, PharmD).
• Proven track record in rare diseases space and experience launching new products.

Responsibilities

• Develop and execute targeted engagement strategies for key accounts in assigned regions.
• Lead regional business planning aligned with corporate goals and cross-functional priorities.
• Collaborate with internal stakeholders to synthesize customer insights and optimize messaging and programs.
• Drive brand awareness, engagement, and treatment adoption through innovative commercial strategies.

Skills

Market development

Biotech/pharma

Stakeholder engagement

US healthcare dynamics

Travel management

Education

Bachelor's degree

MBA/PhD/PharmD preferred

Job description

REGENXBIO Inc. is seeking a Market Development Director to guide regional strategy and launch readiness for rare and neuromuscular therapies. You will lead engagement with treatment centers, align with Sales, Medical Affairs, and Market Access, and shape regional strategies to drive access and adoption.

The role requires 5+ years in biotech/pharma commercial roles, a BA/BS, and a strong track record in rare diseases with international collaboration. Travel up to 60% is expected.